A study found a 94% 6-month survival rate after tandem autologous stem cell transplant for high-risk neuroblastoma, but ...
Panelists discuss how the timing of therapeutic interventions in early-stage myelofibrosis must be carefully weighed against ...
Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...
Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...
In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results